论文部分内容阅读
目的观察重组人血管内皮抑素(恩度)联合多西紫杉醇和顺铂方案(TP)治疗晚期非小细胞肺癌(NSCLC)的近期临床疗效和毒副反应。方法经病理学证实的98例ⅢB～Ⅳ期NSCLC患者随机分为试验组52例,对照组46例,试验组接受恩度联合多西紫杉醇和顺铂方案治疗,对照组单用多西紫杉醇和顺铂方案化疗,用药1周期后评价毒副反应,至少完成2周期治疗后评价疗效。结果试验组有效率为50.0%,临床受益率为78.8%;对照组的有效率为30.4%,临床受益率为58.7%,差异有统计学意义(P<0.05)。毒副反应主要有白细胞减少、血小板减少、恶心、呕吐,肝功损害和肌肉关节痛等,两组比较差异无统计学意义(P>0.05)。结论恩度联合多西紫杉醇和顺铂方案一线治疗晚期NSCLC近期疗效优于单用多西紫杉醇和顺铂方案治疗,且未增加化疗的毒副反应,安全性较好,值得临床推广使用和进一步深入观察。
Objective To observe the short-term clinical efficacy and toxicity of recombinant human endostatin (Endostar) combined with docetaxel and cisplatin (TP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 98 patients with stage ⅢB-Ⅳ NSCLC confirmed by pathology were randomly divided into experimental group (n = 52) and control group (n = 46). The experimental group received Endostar combined docetaxel and cisplatin regimen. The control group received docetaxel alone and Cisplatin chemotherapy, drug toxicity after 1 cycle evaluation, at least complete the evaluation of 2 cycles of treatment efficacy. Results The effective rate of the trial group was 50.0% and the clinical benefit rate was 78.8%. The effective rate of the control group was 30.4% and the clinical benefit rate was 58.7%. The difference was statistically significant (P <0.05). The main side effects were leukopenia, thrombocytopenia, nausea, vomiting, liver damage and muscle and joint pain. There was no significant difference between the two groups (P> 0.05). Conclusions Endeavor combination of docetaxel and cisplatin in the first-line treatment of advanced NSCLC is superior to single-dose docetaxel and cisplatin in the short term, and does not increase the side effects of chemotherapy. It is safe and worthy of clinical promotion and further application In-depth observation.